This review summarized the recent progress of m6A RNA modification in PD clinical research, discussed the effects of m6A on dopaminergic cells from various perspectives and made reasonable speculations about other possible pathways, and outlined the m6A modification sites of specific pathogenic genes (SNCA, PRKN, PINK1, and LRRK2) associated with PD. Here, SNCA is linked to Parkinson disease.